Characteristic | HRG-negative (n = 18) | HRG-positive (n = 14) |
---|---|---|
Age at study entry (years) | 61.6 (15.0) | 56.3 (10.1) |
BMI (kg/m2) | 25.6 (4.3) | 24.9 (4.2) |
Time from diagnosis to metastasis (years) | 5.6 (5.8) | 3.8 (4.4) |
Tumor grade | ||
 1 | 2 (11.8) | 2 (18.2) |
 2 | 11 (64.7) | 7 (63.6) |
 3 | 4 (23.5) | 2 (18.2) |
ECOG score | ||
 0 | 13 (76.5) | 11 (84.6) |
 1 | 4 (23.5) | 2 (15.4) |
 2+ | 0 (0.0) | 0 (0.0) |
Concomitant diseases | ||
 0 or 1 | 8 (44.4) | 10 (76.9) |
 2 to 4 | 10 (55.6) | 2 (15.4) |
 5+ | 0 (0.0) | 1 (7.7) |
Metastasis pattern | ||
 Brain | 0 (0.0) | 1 (7.1) |
 Visceral | 4 (22.2) | 9 (64.3) |
 Bone | 2 (11.1) | 1 (7.1) |
 Other | 12 (66.7) | 3 (21.4) |
Ever received chemotherapy | ||
 No | 18 (100.0) | 14 (100.0) |
 Yes | 0 (0.0) | 0 (0.0) |
Ever received endocrine therapy | ||
 No | 1 (5.6) | 1 (7.1) |
 Yes | 17 (94.4) | 13 (92.9) |
Ever received fulvestrant | ||
 No | 18 (100.0) | 14 (100.0) |
 Yes | 0 (0.0) | 0 (0.0) |
Previous CDK4/6i documented | ||
 No | 0 (0.0) | 1 (7.1)a |
 Yes | 18 (100.0) | 13 (92.9) |
SHERBOC line | ||
 1 | 17 (94.4) | 12 (85.7) |
 2 | 1 (5.6) | 2 (14.3) |